Drug
Pelacarsen sodium clinical trials
Also written ISIS 681257.
A product of Pelacarsen; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses pelacarsen sodium is read from its arms, and is right about nine times in ten.
Testing it · 4
- Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular DiseaseCompletedPhase 2Akcea TherapeuticsNCT03070782Written as ISIS 681257
- Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy PatientsCompletedPhase 1Akcea TherapeuticsNCT03506854Written as ISIS 681257
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on WarfarinCompletedPhase 1Akcea TherapeuticsNCT03426033Written as ISIS 681257
- Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on ClopidogrelCompletedPhase 1Akcea TherapeuticsNCT03392051Written as ISIS 681257
Codes
What other systems call pelacarsen sodium · ClinicalTrials.gg INT016264
- UNII (FDA) D1J27662O8PELACARSEN SODIUMOne source FDA
- NCI Thesaurus C174665Pelacarsen SodiumOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | D1J27662O8 | PELACARSEN SODIUM | One source FDA |
| NCI Thesaurus | C174665 | Pelacarsen Sodium | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.